Close menu




NETRAMARK HOLDINGS INC

Photo credits: pixabay.com

Commented by Stefan Feulner on June 10th, 2025 | 07:05 CEST

Palantir, NetraMark, Qualcomm – Caution, buy signals!

  • AI
  • Biotechnology
  • computing
  • Software
  • Technology

Artificial intelligence is fundamentally changing the economy. It optimizes processes, reduces costs, and creates new business models. Its use in the healthcare and pharmaceutical sectors is currently developing particularly dynamically. Data-based decisions and personalized medicine are significantly increasing efficiency. According to experts, the global market for AI in healthcare could grow disproportionately in the coming years. Many AI companies are still in the early stages of their development.

Read

Commented by Fabian Lorenz on June 3rd, 2025 | 07:20 CEST

A bombshell and a buying opportunity! BioNTech, Bayer, and AI stock NetraMark

  • Biotechnology
  • AI
  • Biotech
  • Pharma

Bombshell news from BioNTech. The Company has announced a collaboration for its cancer pipeline - billions in revenue are on the horizon. The stock has surged significantly. Are there other exciting buying opportunities in the biotech and pharma sectors right now? US politics have recently dampened industry sentiment. The Trump administration wants to lower drug prices. One potential beneficiary is NetraMark, as this AI gem helps industry cut development costs and timelines. In addition, takeover speculation could drive the stock in the second half of the year. And what is Bayer doing? The stock has outperformed the DAX in 2025. Are there reasons to consider buying?

Read

Commented by Nico Popp on May 29th, 2025 | 07:00 CEST

The next AI revolution is being spearheaded by these hidden champions: Palantir, NetraMark, Roche

  • Biotechnology
  • AI
  • Software

Are you still working the same way you did five years ago? Let's be honest: AI has changed a lot. The opportunities are enormous, especially in biotechnology. Already in 2024, one in four venture capital dollars for AI projects went to the healthcare sector, according to Silicon Valley Bank. Although around 80% of the industry already works with AI, there is a wide range of applications, with significant differences between experiments and groundbreaking innovations. We present three AI beneficiaries from the healthcare sector and explain how investors can profit.

Read

Commented by André Will-Laudien on May 27th, 2025 | 07:15 CEST

Up to 1500% with high tech and artificial intelligence – Incredible price movements at Evotec, NetraMark Holdings, and D-Wave

  • Biotechnology
  • Biotech
  • Pharma
  • hightech
  • AI

Artificial intelligence can now be found in all sectors of the economy. Search processes, validations, and historical comparisons now take place in a matter of seconds, and a dramatic leap in productivity is on the horizon. The capital markets have set themselves the task of evaluating these future processes. This is no easy task, as most topics cannot be viewed in isolation. Last week, renewed tariff threats led to a short-term price correction. These losses had to be offset yesterday, with political denials from the US sending share prices skyrocketing again. Under intense pressure, investors now have to decide whether investments promise short- or medium-term success. We use three examples to show how challenging this has become. Where are the opportunities and risks?

Read

Commented by Armin Schulz on May 22nd, 2025 | 07:10 CEST

Overlooked gems? Why artificial intelligence will catapult Novo Nordisk, NetraMark, and UnitedHealth to the forefront

  • Biotechnology
  • AI
  • Technology
  • Healthcare

The pharmaceutical industry is undergoing a historic transformation. Artificial intelligence is compressing drug development times from decades to months, reducing costs by billions, and unlocking therapies for previously untreatable diseases. Algorithms sift through genome data, simulate drug candidates, and optimize clinical trials with a precision that surpasses that of human researchers. This disruption is not only creating medical milestones but also lucrative opportunities for investors. Today, we look at three candidates and analyze the current situation at Novo Nordisk, NetraMark Holdings, and UnitedHealth.

Read

Commented by Stefan Feulner on May 20th, 2025 | 07:05 CEST

Super Micro, NetraMark, Rigetti – Trump push promises potential

  • AI
  • Technology
  • Biotechnology
  • computing

The suspension of tariffs between the two superpowers, the US and China, continues to boost technology and semiconductor stocks such as Nvidia and Super Micro Computer. Tech giant Apple, which initially suffered from the 145% tariffs imposed by US President Donald Trump, is also benefiting enormously from the current deal. AI stocks have also performed well in their wake and are poised for further upward momentum.

Read

Commented by Mario Hose on May 16th, 2025 | 14:00 CEST

Save the date and register now for free: From the raw materials boom to the AI revolution: Leading companies from five continents will present future opportunities on May 21, 2025, at the 15th International Investment Forum (IIF)

  • savethedate
  • iif
  • AI
  • mining
  • DesertGold
  • manuka
  • dynaCERT
  • cenit
  • marinomed
  • altech
  • globexminig
  • powermetallicmines
  • pasinex
  • netramark
  • mmedia
  • Biotechnology
  • reso
  • Technology

If you want to understand the trends of tomorrow, you need to hear directly from the people shaping them today. The 15th International Investment Forum (IIF) gives you that opportunity: On May 21, 2025, CEOs, investors, and thought leaders from across the globe will gather online to share insights from key sectors like industry, defense, mining, cleantech, biotech, AI, and more. In live presentations and interactive discussions, companies such as Germany's CENIT AG, Canada's First Phosphate Corp., dynaCert, Desert Gold, and Australia's Manuka Resources will provide exclusive insights into their strategies. The digital conference will be moderated by Stockhouse media star Lyndsay Malchuk, who is well-known for her incisive interviews. Why should you attend this event?

Read

Commented by Fabian Lorenz on May 13th, 2025 | 07:05 CEST

A bombshell for D-Wave and Siemens Energy! Is AI stock NetraMark too cheap?

  • AI
  • Technology
  • computing
  • Energy

D-Wave has made a spectacular comeback. The reasons are strong figures, positive analyst comments, and cooperation with the auto giant Ford. Is the quantum hot stock heading for a new all-time high? AI gem NetraMark still has a long way to go, but its valuation is extremely exciting. Donald Trump's latest statements show that drug prices must come down. Pharma and biotech companies can achieve this by using NetraMark's AI. The stock appears cheap and also has takeover potential. Siemens Energy shares are unstoppable. However, analysts' opinions continue to diverge. On the one hand, the price target is being raised, while on the other, a sell recommendation is being issued. What to do?

Read

Commented by Nico Popp on May 8th, 2025 | 07:00 CEST

Data as a return booster: NetraMark, BioNTech, and Palantir Technologies

  • AI
  • Biotechnology
  • Biotech
  • Software

It is common knowledge by now that data is the raw material of the 21st century. However, only a few truly understand the many ways in which this digital raw material can now be processed. Today, we present three companies - NetraMark, BioNTech, and Palantir Technologies - whose business models stand to benefit significantly from modern data processing and AI. We also examine whether there is any potential for collaboration between these companies.

Read

Commented by André Will-Laudien on May 5th, 2025 | 07:20 CEST

Biotech is back with artificial intelligence! Evotec, NetraMark Holdings, Bayer, and BioNTech

  • Biotechnology
  • Biotech
  • Pharma

Artificial intelligence has arrived in health research! Whenever large volumes of data need to be analyzed, patterns recognized, or results condensed, immense computing power is required. The goal is to detect complex structures, automate processes, and make real-time decisions. The use of AI in medicine and pharmaceutical development is making good progress because time and high validation capability are key here. Some companies have already recognized the signs of the times and are working hard on the new technologies. On the stock market, this is often the starting signal for significantly higher valuations. Evotec, Bayer, and BioNTech are well-known European players, while Canadian company NetraMark Holdings has seen its share price increase sevenfold since fall 2024. What is behind this surge?

Read